Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2002-08-01
2010-11-02
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100, C424S152100, C424S156100, C424S172100, C514S002600
Reexamination Certificate
active
07824680
ABSTRACT:
The invention provides methods for detecting and inhibiting angiogenesis, endothelial cell adhesion, and endothelial cell migration using agents which inhibit the specific binding of integrin α4β1 to one or more of its ligands. The invention further provides methods for screening test compounds for their ability to inhibit angiogenesis, endothelial cell adhesion, or endothelial cell migration by employing agents which inhibit the specific binding of integrin α4β1 to one or more of its ligands. The invention additionally relates to methods for isolating endothelial progenitor cells which express integrin α4β1. The methods of the invention are useful in, for example, diagnosing and inhibiting pathological conditions that are associated with angiogenesis, endothelial cell adhesion, and/or endothelial cell migration. The invention's methods are also useful in isolating endothelial progenitor cells, and in determining the mechanisms that underlie angiogenesis, development, wound healing, and the function of the female reproductive system.
REFERENCES:
patent: 4894326 (1990-01-01), Matsuura et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5523229 (1996-06-01), Feinberg et al.
patent: 5688913 (1997-11-01), Arrhenius et al.
patent: 5730978 (1998-03-01), Wayner
patent: 5780426 (1998-07-01), Palladino et al.
patent: 5869448 (1999-02-01), Arrhenius et al.
patent: 5980887 (1999-11-01), Isner et al.
patent: 5981478 (1999-11-01), Ruoslahti et al.
patent: 6034056 (2000-03-01), Dutta
patent: 6034057 (2000-03-01), Dutta
patent: 6252043 (2001-06-01), Hession et al.
patent: 6306840 (2001-10-01), Adams et al.
patent: 6376538 (2002-04-01), Adams et al.
patent: 6713604 (2004-03-01), Kogan et al.
patent: 6818617 (2004-11-01), Niewiarowski et al.
patent: 2002/0172675 (2002-11-01), Varner
patent: 2004/0220148 (2004-11-01), Stilz et al.
patent: WO 96/01644 (1996-01-01), None
patent: WO 97/18838 (1997-05-01), None
patent: WO 00/15247 (2000-03-01), None
Saiki, I., et al, Jpn. J. Cancer Res., 81: 668-675, 1990.
Sanchez-Aparicio, P. et al., The Journal of Cell Biology, 126(1): 271-279, 1994.
Koch, A.E., et al. Nature, 376: 517-519, 1995.
Maurer, C.A. et al., Int. J. Cancer (Pred. Oncol.), 79: 76-81, 1998.
Vanderslice, P. et al., Angiogenesis, 2: 265-275, 1998.
Massia, S.P., et al, J. Biol. Chemistry, 267(20): 14019-14026, 1992.
Sheppard, A.M., et al. Cell Adhesion and Communication, 2: 27-43, 1994.
Detmar, M. et al. J. Invest. Dermatol. 111: 1-6, 1998).
Saiki et al. (1990) “Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD),” Jpn. J. Cancer Res. 81:668-675.
Sanchez-Aparicio et al. (1994) “Activation of the α4β1 integrin through the β1 subunit induces recognition of the RGDS sequence in fibronectin,” J. Cell Biol. 126:271-279.
Yednock et al. (1995), “α4β1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand,” J. Biol. Chem. 270:28740-28750.
Koch et al. (1995) “Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1,” Nature 376:517-519.
Maurer et al. (1998) “Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer,” Int. J. Cancer (Pred. Oncol.) 79:76-81.
Clements JM et al. (1994) “Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin,” J. Cell. Sci. 107:2127-2135.
Komoriya A et al. (1991) “The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine (LDV),” J. Biol. Chem. 266:15075-15079.
Cardarelli PM et al. (1994) “Cyclic RGD peptide inhibits alpha 4 beta 1 interaction with connecting segment 1 and vascular cell adhesion molecule,” J. Biol. Chem. 269:18668-18673.
Marcinkiewicz et al. (1999) “EC3, A novel heterodimeric disintegrin fromEchis carinatusvenom, inhibits α4 and α5 integrins in an RGD-independent manner,” J. Biol. Chem. 274:12468-12473.
Marcinkiewicz et al. (2000) “Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin α9β1 with VCAM-1, tenascin-C, and osteopontin,” J. Biol. Chem. 275:31930-31937.
Kim et al. (2000) “Regulation of Angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin,” Amer. J. Path. 156:1345-1362.
Garmy-Susini et al. (2005) “Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation,” J. Clin. Invest. 115(6):1542-1551.
Ausprunk et al., “Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels,” Amer J Pathol, 79:597-628 (1975) abstract.
Bochner et al., “Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules,” J Exp Med, 173:1553-1556 (1991).
Brando et al., “EC3, a heterodimeric disintegrin fromEchis carinatus, inhibits human and murine alpha-4 integrin and attenuates lymphocyte infiltration of langerhans islets in pancreas and salivary glands in nonobese diabetic mice,” Biochem Biophys Res Commun, 267:413-417 (2000).
Cardarelli et al., “Cyclic RGD peptide inhibits alpha-4/beta-1 interaction with connecting segment 1 and vascular cell adhesion molecule,” J Biol Chem, 269:18668-18673 (1994).
Chisholm et al., “Monoclonal antibodies to the integrin alpha-4 subunit inhibit the murine contact hypersensitivity response,” Eur J Immunol, 23:682-688 (1993) abstract.
Clements et al., “Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin,” J Cell Sci, 107:2127-2135 (1994).
Curley et al., “Integrin antagonists,” Cell Mol Life Sci, 56:427-441 (1999).
Dittel et al., “Regulation of human B-cell precursor adhesion to bone marrow stromal cells by cytokines that exert opposing effects on the expression of vascular cell adhesion molecule-I (VCAM-1),” Blood, 81:2272-2282 (1993).
Dudgeon et al., “Expression and characterization of a very-late antigen-4 (alpha-4/beta-1) integrin-binding fragment of vascular cell-adhesion molecule-1,” Eur J Biochem, 226:517-523 (1994) abstract.
Garcia-Pardo et al., “Two novel monoclonal antibodies to fibronectin that recognize the Hep II and CS-1 regions respectively: their differential effect on lymphocyte adhesion,” Biochem Biophys Res Commun, 186:135-42 (1992) abstract.
Grant et al., “Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro,” Cell, 58:933-943 (1989) abstract.
Hemler et al., “Characterization of five distinct cell surface heterodimers each with a common 130,000 molecular weight beta subunit,” J Biol Chem, 262:3300-3309 (1987).
Hemler et al., “Characterization of the cell surface heterodimer VLA-4 and related peptides,” J Biol Chem, 262:11478-11485 (1987).
Holzmann et al., “Identification of a murine Peyer's patch—specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha,” Cell, 56:37-46 (1989).
Humphries et al., A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells, Science, 233:467-470 (1986).
Humphries et al., “Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melano
Harris Alana M.
Holleran Anne L
Medlen & Carroll LLP
The Regents of the University of California
LandOfFree
Methods for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228214